Autopsy report · NCT04923802

Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)

“Unable to recruit sufficient numbers of patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

GeneCast Biotechnology Co., Ltd.

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer; Neoantigen; Next-generation Sequencing; Biomarker

Participants

13

Sites

1

Countries

China

Trials that died the same way

• Project 4A: Inspiratory Muscle Training and Diaphragm Strength
  “Unable to recruit sufficient number of patients” (98% match in meaning)
• The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer
  “Unable to recruit sufficient patients” (92% match in meaning)
• Bone Healing in Healthy and Post-menopausal Osteoporotic Women
  “Unable to recruit suitable patients” (88% match in meaning)
• Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases
  “unable to recruit patients” (86% match in meaning)
• Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis
  “not able to recruit patients” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.